|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| {{drugbox
| | #REDIRECT[[Reviparin sodium]] |
| | IUPAC_name =
| |
| | image =
| |
| | CAS_number = 9041-08-1
| |
| | ATC_prefix = B01
| |
| | ATC_suffix = AB08
| |
| | PubChem =
| |
| | DrugBank =
| |
| | chemical_formula =
| |
| | molecular_weight =
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category=
| |
| | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| |
| | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| |
| | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| |
| | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
| {{CMG}}
| |
| | |
| | |
| | |
| '''Reviparin''' is an antithrombotic in the [[heparin]] group.
| |
| | |
| ==External links==
| |
| * {{MeshName|reviparin}}
| |
| * {{cite journal |author=Yusuf S, Mehta SR, Xie C, ''et al'' |title=Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation |journal=JAMA |volume=293 |issue=4 |pages=427-35 |year=2005 |pmid=15671427 |doi=10.1001/jama.293.4.427}}
| |
| | |
| {{Antithrombotics}}
| |
| | |
| [[Category:Drugs]]
| |
| | |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |